1. Home
  2. RDI vs CVKD Comparison

RDI vs CVKD Comparison

Compare RDI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDI
  • CVKD
  • Stock Information
  • Founded
  • RDI 1937
  • CVKD 2022
  • Country
  • RDI United States
  • CVKD United States
  • Employees
  • RDI N/A
  • CVKD N/A
  • Industry
  • RDI Movies/Entertainment
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • RDI Consumer Discretionary
  • CVKD Health Care
  • Exchange
  • RDI Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • RDI 30.6M
  • CVKD 29.5M
  • IPO Year
  • RDI N/A
  • CVKD 2023
  • Fundamental
  • Price
  • RDI $1.27
  • CVKD $12.90
  • Analyst Decision
  • RDI Hold
  • CVKD Strong Buy
  • Analyst Count
  • RDI 1
  • CVKD 1
  • Target Price
  • RDI $2.40
  • CVKD $32.00
  • AVG Volume (30 Days)
  • RDI 31.9K
  • CVKD 34.8K
  • Earning Date
  • RDI 08-13-2025
  • CVKD 08-06-2025
  • Dividend Yield
  • RDI N/A
  • CVKD N/A
  • EPS Growth
  • RDI N/A
  • CVKD N/A
  • EPS
  • RDI N/A
  • CVKD N/A
  • Revenue
  • RDI $205,644,000.00
  • CVKD N/A
  • Revenue This Year
  • RDI $7.47
  • CVKD N/A
  • Revenue Next Year
  • RDI $13.22
  • CVKD N/A
  • P/E Ratio
  • RDI N/A
  • CVKD N/A
  • Revenue Growth
  • RDI N/A
  • CVKD N/A
  • 52 Week Low
  • RDI $1.17
  • CVKD $5.70
  • 52 Week High
  • RDI $1.89
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • RDI 43.09
  • CVKD 49.22
  • Support Level
  • RDI $1.21
  • CVKD $11.00
  • Resistance Level
  • RDI $1.31
  • CVKD $13.56
  • Average True Range (ATR)
  • RDI 0.06
  • CVKD 1.13
  • MACD
  • RDI -0.01
  • CVKD 0.23
  • Stochastic Oscillator
  • RDI 29.95
  • CVKD 78.32

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: